Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications

Author(s): Emily C. Vogler, Jorge Busciglio

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 15 , 2014


Become EABM
Become Reviewer
Call for Editor

Abstract:

So far, therapeutics focusing on reducing levels of amyloid beta for treatment of Alzheimer’s disease have not been successful in completing clinical trials to come to market, suggesting the need of a wider perspective and the consideration of novel targets of intervention to slow or halt the progression of this disease. One such target is soluble amyloid beta in oligomeric forms, which have been demonstrated to bind with high affinity to zinc released during synaptic activity. This review considers the interaction of AβO and zinc and the role of zinc in neurotransmission along with possible neurotoxic effects of this interaction. Finally, it also discusses recent experimental data in animal models that have translated into potential treatments for AD based on the modulation of hyperexcitability and zinc homeostasis.

Keywords: Amyloid beta, oligomers, zinc, synapses, Alzheimer’s disease.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 15
Year: 2014
Published on: 11 May, 2014
Page: [2520 - 2524]
Pages: 5
DOI: 10.2174/13816128113199990510
Price: $65

Article Metrics

PDF: 27